Here are some other things to think about when choosing a treatment:
Is it quick to mix and fast to infuse?
Is it room-temperature stable?
How does treatment work when I’m on the go?
Is the packaging small enough to take with me?
aPatients with Hemophilia A or B with inhibitors, acquired hemophilia or Glanzmann’s thrombasthenia with resistance to platelets can redose every 2 hours. Patients with factor VII deficiency can redose every 4-6 hours.
Here are some other things to think about when choosing a treatment:
Is it quick to mix and fast to infuse?
Is it room-temperature stable?
How does treatment work when I’m on the go?
Is the packaging small enough to take with me?
NovoSeven® RT helps the broadest range of patients with bleeding disorders.
Experience you can trust:
More than 30 years of experience helping people with rare bleeding disorders treat bleeds.b
First rFVIIa approved for:
Hemophilia A or B with inhibitors
Only rFVIIa approved for:
bFor people with hemophilia A or B with inhibitors.
cIn people with acquired hemophilia, NovoSeven® RT is only indicated for adults.
dFor people with hemophilia A or B with inhibitors.
eIn people with acquired hemophilia, NovoSeven® RT is only indicated for adults.
fFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors.
gIn patients with hemophilia A or B with inhibitors.
hIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
iPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute. All information from FEIBA Package Insert.
jRedosing time does not correlate to body weight.
kRedosing time is based on maximum daily dose and the type of bleed.
The MixPro® syringe means no extra steps to fill a syringe with diluent.
Get a Ready-to-Travel Case to make storing supplies at home or on the go more convenient.
To order a travel case please contact a Novo Nordisk Hemophilia Community Liaison (HCL).
Once you and your health care provider decide that NovoSeven® RT is right for you, we’re here to help you successfully start your treatment.
Watch our videos to hear people with bleeding disorders talk about traveling and infusing on the go with NovoSeven® RT.
You may be eligible to try it for free.l To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoCare® Specialist.
lPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
NovoSeven® RT may cause serious side effects, including:
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:
NovoSeven® RT may cause serious side effects, including: